TY - JOUR
T1 - The Benefits of Interferon Treatment in Patients Without Sustained Viral Response After Living Donor Liver Transplantation for Hepatitis C
AU - Ikegami, T.
AU - Taketomi, A.
AU - Soejima, Y.
AU - Yoshizumi, T.
AU - Fukuhara, T.
AU - Kotoh, K.
AU - Shimoda, S.
AU - Kato, M.
AU - Maehara, Y.
PY - 2009/12
Y1 - 2009/12
N2 - Although it has been recognized that interferon (IFN) treatment is crucial for recurrent hepatitis C after liver transplantation, its benefits have not been determined among patients without a sustained viral response (SVR). Methods: Eighty patients who received IFN plus ribavirin treatment after living donor liver transplantation were grouped as follows: group I (n = 18) SVR; group II (n = 25) no-SVR but viral response [VR] positive; Group III (n = 13) no-VR but biochemical response [BR] positive; and group IV (n = 24) no-VR and no-BR. Results: In groups II and III, not only the histological activity grade and fibrosis stage, but also the serum parameters including transaminases and type IV collagen were stable for 3 years after induction of IFN-based treatment. In group I, the activity grade and fibrosis stage significantly improved (P < .01). In group IV, the fibrosis stage significantly deteriorated (P < .01); the serum transaminases and type IV collagen were significantly higher than the other groups (P < .01). The mean duration of IFN treatment was significantly longer among group II (96 weeks) compared with the other cohorts (P < .05). The 5-year graft survival rate in groups II (91%) and III (100%) were comparable to those of group I (100%); group IV (62%) was significantly lower than the other groups (P < .05). Conclusion: IFN treatment was beneficial even among subjects with IFN-dependent VR or BR, although they did not achieve SVR.
AB - Although it has been recognized that interferon (IFN) treatment is crucial for recurrent hepatitis C after liver transplantation, its benefits have not been determined among patients without a sustained viral response (SVR). Methods: Eighty patients who received IFN plus ribavirin treatment after living donor liver transplantation were grouped as follows: group I (n = 18) SVR; group II (n = 25) no-SVR but viral response [VR] positive; Group III (n = 13) no-VR but biochemical response [BR] positive; and group IV (n = 24) no-VR and no-BR. Results: In groups II and III, not only the histological activity grade and fibrosis stage, but also the serum parameters including transaminases and type IV collagen were stable for 3 years after induction of IFN-based treatment. In group I, the activity grade and fibrosis stage significantly improved (P < .01). In group IV, the fibrosis stage significantly deteriorated (P < .01); the serum transaminases and type IV collagen were significantly higher than the other groups (P < .01). The mean duration of IFN treatment was significantly longer among group II (96 weeks) compared with the other cohorts (P < .05). The 5-year graft survival rate in groups II (91%) and III (100%) were comparable to those of group I (100%); group IV (62%) was significantly lower than the other groups (P < .05). Conclusion: IFN treatment was beneficial even among subjects with IFN-dependent VR or BR, although they did not achieve SVR.
UR - http://www.scopus.com/inward/record.url?scp=71249097940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71249097940&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2009.08.070
DO - 10.1016/j.transproceed.2009.08.070
M3 - Article
C2 - 20005378
AN - SCOPUS:71249097940
SN - 0041-1345
VL - 41
SP - 4246
EP - 4252
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 10
ER -
